Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

GIPC proteins negatively modulate Plexind1 signaling during vascular development.

Carretero-Ortega J, Chhangawala Z, Hunt S, Narvaez C, Menéndez-González J, Gay CM, Zygmunt T, Li X, Torres-Vázquez J.

Elife. 2019 May 3;8. pii: e30454. doi: 10.7554/eLife.30454.

2.

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.

Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA.

Clin Cancer Res. 2019 Feb 13. doi: 10.1158/1078-0432.CCR-18-0968. [Epub ahead of print] Review.

PMID:
30760478
3.

Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.

Della Corte CM, Gay CM, Byers LA.

Cancer. 2019 Feb 15;125(4):496-498. doi: 10.1002/cncr.31863. Epub 2019 Jan 8. No abstract available.

PMID:
30620399
4.

ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer.

Della Corte CM, Gay CM, Byers LA, Morgillo F.

EBioMedicine. 2019 Jan;39:5-6. doi: 10.1016/j.ebiom.2018.12.008. Epub 2018 Dec 13. No abstract available.

5.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

PMID:
30322867
6.

Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.

Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA.

Clin Cancer Res. 2019 Jan 1;25(1):346-357. doi: 10.1158/1078-0432.CCR-18-1129. Epub 2018 Sep 26.

PMID:
30257981
7.

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.

Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL.

Cancer Discov. 2018 Sep;8(9):1156-1175. doi: 10.1158/2159-8290.CD-17-1033. Epub 2018 Jul 16.

PMID:
30012853
8.

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C.

Cell Rep. 2018 Apr 3;23(1):194-212.e6. doi: 10.1016/j.celrep.2018.03.063.

9.

Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.

Sen T, Gay CM, Byers LA.

Transl Lung Cancer Res. 2018 Feb;7(1):50-68. doi: 10.21037/tlcr.2018.02.03. Review.

10.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.

Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA.

Oncotarget. 2017 Apr 25;8(17):28575-28587. doi: 10.18632/oncotarget.15338.

11.

Giving AXL the axe: targeting AXL in human malignancy.

Gay CM, Balaji K, Byers LA.

Br J Cancer. 2017 Feb 14;116(4):415-423. doi: 10.1038/bjc.2016.428. Epub 2017 Jan 10. Review.

12.

Thymoma complicated by acquired amegakaryocytic thrombocytopenia and pure red cell aplasia.

Gay CM, William WN Jr, Wang SA, Oo TH.

J Natl Compr Canc Netw. 2014 Nov;12(11):1505-9.

PMID:
25361796
13.

Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1.

Zygmunt T, Gay CM, Blondelle J, Singh MK, Flaherty KM, Means PC, Herwig L, Krudewig A, Belting HG, Affolter M, Epstein JA, Torres-Vázquez J.

Dev Cell. 2011 Aug 16;21(2):301-14. doi: 10.1016/j.devcel.2011.06.033. Epub 2011 Jul 28.

14.

Diverse functions for the semaphorin receptor PlexinD1 in development and disease.

Gay CM, Zygmunt T, Torres-Vázquez J.

Dev Biol. 2011 Jan 1;349(1):1-19. doi: 10.1016/j.ydbio.2010.09.008. Epub 2010 Sep 27. Review.

15.

Determination of 1-benzo[b]thien-2-ylethanone and related impurities by high performance liquid chromatography.

Shada DM, Wong CF, Elrod L Jr, Morley JA, Gay CM.

J Pharm Biomed Anal. 1996 Feb;14(4):501-10.

PMID:
8729650
16.

Agenda for action.

Gay CM.

J Am Med Womens Assoc (1972). 1977 Jan;32(1):7-9. No abstract available.

PMID:
188876

Supplemental Content

Support Center